[CAS NO. 374886-51-8] ASP2535
PRODUCTS SPECIFICATIONS [374886-51-8]
DESCRIPTION [374886-51-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 382.42 |
| Molecular Formula | C22H18N6O |
| SMILES | CC(C1=NN=C(C2=CC=C(C3=CC=CC=C3)N=C2)N1C4=CC=CC5=NON=C54)C |
Summary
ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease [1] .
IC50 & Target
GlyT1 [1]
In Vitro
ASP2535 potently inhibits rat GlyT1 (IC
50
=92 nM) with 50-fold selectivity over rat glycine transporter-2 (GlyT2) in vitro
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ASP2535 (0.3-3 mg/kg; p.o) attenuates working memory deficit in MK-801-treated mice and visual learning deficit in neonatally phencyclidine (PCP)-treated mice
[1]
.
ASP2535 (1-3 mg/kg, p.o.) also improves the PCP-induced deficit in prepulse inhibition in rats
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 5-week-old male ddY mice [1] |
| Dosage: | 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg |
| Administration: | Oral administration |
| Result: | Significantly attenuated the MK-801-induced decrease in alternation rate. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |